PRESS RELEASE published on 11/04/2025 at 11:38, 1 month ago Original-Research: MaaT Pharma SACA (von First Berlin Equity Research GmbH): BUY First Berlin Equity Research initiates coverage on MaaT Pharma SACA with a BUY rating and EUR 17 price target. MaaT Pharma focuses on microbiome-based therapies for oncology, with high clinical impact and late-stage pipeline Oncology BUY Rating Clinical-stage Biotechnology MaaT Pharma SACA Microbiome-based Therapies
BRIEF published on 11/04/2025 at 07:35, 1 month ago MaaT Pharma Third Quarter 2025 Financial Results and Financing Update Financial Results MaaT Pharma European Medicines Agency Xervyteg® Clinigen Partnership
PRESS RELEASE published on 11/04/2025 at 07:30, 1 month ago Inside Information / News release on accounts, results MaaT Pharma reports Q3 2025 financial results, secured financing, and partnership updates. Cash position of €22.4 million. Revenues increased by 45% year-over-year Revenues Financing Partnership MaaT Pharma Q3 2025
BRIEF published on 10/13/2025 at 14:52, 1 month 22 days ago Crossing of Thresholds by Invus Public Equities in MAAT PHARMA Voting Rights Crossing Thresholds Transfer Of Shares MaaT Pharma Invus Public Equities
BRIEF published on 10/06/2025 at 14:59, 1 month 29 days ago Symbiosis LLC Reduces Stake in MAAT PHARMA Voting Rights Crossing Thresholds Transfer Of Shares MaaT Pharma Symbiosis LLC
BRIEF published on 09/17/2025 at 07:35, 2 months 17 days ago MaaT Pharma unveils its 2025 half-year results Revenue Growth Half-year Results EIB Financing MaaT013 Efficiency Clinigen Agreement
PRESS RELEASE published on 09/17/2025 at 07:30, 2 months 17 days ago Inside Information / Information on annual revenues MaaT Pharma presents positive Half Year 2025 Results with promising data from Phase 3 trial of MaaT013 in aGvHD. Company strengthens position with partnerships and financing Partnerships Phase 3 Trial Half Year Results MaaT Pharma AGvHD
BRIEF published on 07/28/2025 at 07:35, 4 months 7 days ago MaaT Pharma Secures €37.5 Million Loan to Boost Hemato-Oncology Programs Clinical Development EIB Loan Hemato-oncology Microbiome Therapy Xervyteg® Approval
PRESS RELEASE published on 07/28/2025 at 07:30, 4 months 7 days ago Inside Information / Other news releases MaaT Pharma secures €37.5 million loan from the European Investment Bank to advance clinical programs in Hemato-Oncology. Funding supports late-stage assets Xervyteg® and MaaT033 European Investment Bank Clinical Programs Loan MaaT Pharma Hemato-oncology
BRIEF published on 06/24/2025 at 20:05, 5 months 10 days ago MaaT Pharma General Meeting: Results and Appointments Kepler Cheuvreux Resolutions General Assembly MaaT Pharma Appointment Of President
Published on 12/05/2025 at 02:35, 2 hours 47 minutes ago Future Fuels Initates Drill Permitting at Hornby; Marketing Update
Published on 12/05/2025 at 01:00, 4 hours 22 minutes ago BEACN Closes First Tranche of Non-Brokered Private Placement
Published on 12/04/2025 at 23:05, 6 hours 17 minutes ago BlackBerry to Announce Third Quarter Fiscal Year 2026 Results on December 18, 2025
Published on 12/04/2025 at 23:00, 6 hours 22 minutes ago NXT Energy Solutions Completes Data Acquisition for SFD Survey
Published on 12/05/2025 at 03:30, 1 hour 51 minutes ago CGTN: What makes cooperation between China and France a two-way success
Published on 12/04/2025 at 23:50, 5 hours 31 minutes ago EQS-Adhoc: Dexus Finance Pty Limited: Dexus prices A$500 million of subordinated notes
Published on 12/04/2025 at 20:25, 8 hours 56 minutes ago Newmark Appoints Globally Recognized Real Estate Executive Peter Trollope to Lead Occupier Solutions
Published on 12/04/2025 at 20:15, 9 hours 6 minutes ago Galimedix Therapeutics presents compelling Phase 1 study results showing excellent safety and pharmacokinetics with oral small molecule GAL-101 at CTAD 2025
Published on 12/04/2025 at 19:10, 10 hours 11 minutes ago SCHOTT Pharma’s preliminary results for fiscal year 2025; outlook for FY 2026 and update of mid-term guidance
Published on 12/04/2025 at 18:00, 11 hours 22 minutes ago Information concerning the total number of voting rights and shares in the share capital as of November 28, 2025
Published on 12/04/2025 at 17:45, 11 hours 37 minutes ago MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL
Published on 12/04/2025 at 17:44, 11 hours 37 minutes ago Net profit attributable to owners of the parent up by 63% to €122 million, driven by business resilience and the improvement in Elior's contribution
Published on 12/04/2025 at 07:01, 22 hours 21 minutes ago bioMérieux launches leading endocrinology testing offer dedicated to enhancing equine health
Published on 12/03/2025 at 18:00, 1 day 11 hours ago Declaration of voting rights at the end of November 2025
